Completed PHASE4 INTERVENTIONAL 2-arm NCT02208050

A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS

A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis

Sponsor: University College Dublin

Conditions Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Interventions Fampridine Placebo

Updated 7 times since 2017 Last updated: Jul 8, 2021 Started: Feb 21, 2014 Primary completion: Feb 16, 2016 Completion: Feb 16, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02208050, this PHASE4 trial focuses on Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis and remains completed. Sponsored by University College Dublin, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Sep 2021 [monthly]

Completed PHASE4
Sep 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE4

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University College Dublin

Data source: University College Dublin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dublin, Ireland